AR093635A1 - Inhibidores de la tirosina quinasa de bruton, metodo de tratamiento, compuesto, combinacion, formulacion - Google Patents

Inhibidores de la tirosina quinasa de bruton, metodo de tratamiento, compuesto, combinacion, formulacion

Info

Publication number
AR093635A1
AR093635A1 ARP130104376A ARP130104376A AR093635A1 AR 093635 A1 AR093635 A1 AR 093635A1 AR P130104376 A ARP130104376 A AR P130104376A AR P130104376 A ARP130104376 A AR P130104376A AR 093635 A1 AR093635 A1 AR 093635A1
Authority
AR
Argentina
Prior art keywords
methyl
dihydro
oxo
ylamino
pyridin
Prior art date
Application number
ARP130104376A
Other languages
English (en)
Inventor
Mahadevan Iyer Raman
Ibrahim Laine Dramane
Javier Lopez-Tapia Francisco
E Phillips Jonathan
Stevenson Christopher
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR093635A1 publication Critical patent/AR093635A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Inorganic Chemistry (AREA)

Abstract

Método de tratamiento o mejora para el asma que comprende administrar mediante inhalación de inhibidores de Btk 6-terc-butil-8-fluoro-2-{3-hidroximetil-4-[1-metil-5-(1-metil-1,2,3,4,5,6-hexahidro-[3,4]bipiridinil-6-ilamino)-6-oxo-1,6-dihidro-piridazin-3-il]-piridin-2-il}-2H-ftalazin-1-ona, 2-(2-{3-[5-(5-azetidin-1-ilmetil-1-metil-1H-pirazol-3-ilamino)-1-metil-6-oxo-1,6-dihidro-piridazin-3-il]-2-hidroximetil-fenil}-8-fluoro-1-oxo-1,2-dihidro-isoquinolin-6-il)-2-metil-propionitrilo y 6-terc-butil-2-[2-hidroximetil-3-(5-{5-[(2-metoxi-etilamino)-metil]-piridin-2-ilamino}-6-oxo-1,6-dihidro-piridin-3-il)-fenil]-3,4-dihidro-2H-isoquinolin-1-ona, formulaciones de los mismos, y métodos de tratamiento del asma, tal como se indica en la presente memoria. Reivindicación 3: Formulación que comprende 6-terc-butil-8-fluoro-2-{3-hidroximetil-4-[1-metil-5-(1-metil-1,2,3,4,5,6-hexahidro-[3,4]bipiridinil-6-ilamino)-6-oxo-1,6-dihidro-piridazin-3-il]-piridin-2-il}-2H-ftalazin-1-ona micronizada y lactosa micronizada. Reivindicación 6: Formulación que comprende 2-(2-3-[5-(5-azetidin-1-ilmetil-1-metil-1H-pirazol-3-ilamino)-1-metil-6-oxo-1,6-dihidro-piridazin-3-il]-2-hidroximetil-fenil}-8-fluoro-1-oxo-1,2-dihidro-isoquinolin-6-il)-2-metil-propionitrilo micronizado y lactosa micronizada. Reivindicación 9: Formulación que comprende 6-terc-butil-2-[2-hidroximetil-3-(5-{5-[(2-metoxi-etilamino)-metil]-piridin-2-ilamino}-6-oxo-1,6-dihidro-piridin-3-il)-fenil]-3,4-dihidro-2H-isoquinolin-1-ona micronizada y lactosa micronizada. Reivindicación 12: Compuesto de fórmula (1), o una sal farmacéuticamente aceptable del mismo.
ARP130104376A 2012-11-30 2013-11-28 Inhibidores de la tirosina quinasa de bruton, metodo de tratamiento, compuesto, combinacion, formulacion AR093635A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261731510P 2012-11-30 2012-11-30

Publications (1)

Publication Number Publication Date
AR093635A1 true AR093635A1 (es) 2015-06-17

Family

ID=49681019

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130104376A AR093635A1 (es) 2012-11-30 2013-11-28 Inhibidores de la tirosina quinasa de bruton, metodo de tratamiento, compuesto, combinacion, formulacion

Country Status (12)

Country Link
US (1) US20150290192A1 (es)
EP (1) EP2925323B1 (es)
JP (1) JP6042995B2 (es)
KR (1) KR20150075115A (es)
CN (1) CN104968346B (es)
AR (1) AR093635A1 (es)
BR (1) BR112015010121A2 (es)
CA (1) CA2891634A1 (es)
HK (1) HK1215855A1 (es)
MX (1) MX2015006457A (es)
RU (1) RU2015122218A (es)
WO (1) WO2014083026A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101763504B1 (ko) * 2013-03-05 2017-07-31 에프. 호프만-라 로슈 아게 브루톤 티로신 키나아제의 억제제
PT3247699T (pt) 2015-01-22 2019-08-06 Sanofi Aventis Deutschland Processo para a produção de 2-[4-(ciclopropanocarbonil)fenil]-2-metil-propanonitrilo
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2019071147A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. INHIBITORS OF KINASE P38 REDUCING EXPRESSION OF DUX4 GENE AND DOWNSTREAM GENES FOR THE TREATMENT OF FSHD
AU2020361747A1 (en) * 2019-10-11 2022-04-28 Glenmark Specialty S.A. An inhalable dry powder composition for pulmonary diseases
CN111358773B (zh) * 2020-04-10 2021-03-30 广州南鑫药业有限公司 一种帕拉米韦干粉吸入剂及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI0820279T1 (en) 1995-04-14 2002-12-31 Smithkline Beecham Corporation Metered dose inhaler for albuterol
TW533865U (en) 1997-06-10 2003-05-21 Glaxo Group Ltd Dispenser for dispensing medicament and actuation indicating device
US6390291B1 (en) 1998-12-18 2002-05-21 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6352152B1 (en) 1998-12-18 2002-03-05 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6315112B1 (en) 1998-12-18 2001-11-13 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6119853A (en) 1998-12-18 2000-09-19 Glaxo Wellcome Inc. Method and package for storing a pressurized container containing a drug
WO2007117661A2 (en) * 2006-04-03 2007-10-18 Teva Pharmaceutical Industries Ltd, Drug microparticles
NZ586916A (en) * 2008-02-05 2012-06-29 Hoffmann La Roche Novel pyridinones and pyridazinones
TWI491416B (zh) * 2008-12-24 2015-07-11 Daiichi Sankyo Co Ltd 吸入用乾燥粉末醫藥組成物
US8299077B2 (en) * 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
NZ604004A (en) 2010-05-07 2014-06-27 Gilead Connecticut Inc Pyridone and aza-pyridone compounds and methods of use
WO2011160920A1 (en) * 2010-06-22 2011-12-29 Chiesi Farmaceutici S.P.A. Dry powder formulation comprising an antimuscarinic drug
AR082590A1 (es) * 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton
JP5859640B2 (ja) * 2011-05-17 2016-02-10 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ブルトンチロシンキナーゼ阻害剤
KR20140052032A (ko) * 2011-08-17 2014-05-02 에프. 호프만-라 로슈 아게 브루톤 티로신 키나아제의 억제제
US20130104881A1 (en) * 2011-10-31 2013-05-02 Laboratorio Pablo Cassara S.R.L. Stabilized Metered Dose Inhaler

Also Published As

Publication number Publication date
EP2925323B1 (en) 2017-05-17
HK1215855A1 (zh) 2016-09-23
JP6042995B2 (ja) 2016-12-14
KR20150075115A (ko) 2015-07-02
CN104968346B (zh) 2017-06-27
CA2891634A1 (en) 2014-06-05
BR112015010121A2 (pt) 2017-07-11
US20150290192A1 (en) 2015-10-15
RU2015122218A (ru) 2017-01-10
WO2014083026A1 (en) 2014-06-05
MX2015006457A (es) 2015-08-14
EP2925323A1 (en) 2015-10-07
CN104968346A (zh) 2015-10-07
JP2016503419A (ja) 2016-02-04

Similar Documents

Publication Publication Date Title
AR093635A1 (es) Inhibidores de la tirosina quinasa de bruton, metodo de tratamiento, compuesto, combinacion, formulacion
PE20160521A1 (es) Inhibidores de autotaxina que comprenden un nucleo ciclico de anillo heteroaromatico-bencil-amida
CR20130649A (es) Liberación modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida solubilizada utilizando ácidos orgánicos
NZ739339A (en) Apoptosis signal-regulating kinase inhibitor
NI201600098A (es) Composiciones farmacéuticas que comprenden azd9291
PE20141686A1 (es) Compuestos de piperazina alquilados como inhibidores de actividad btk
HRP20182059T1 (hr) Polimorfi i soli 6-(1h-indol-4-il)-4-(5-{[4-(1-metiletil)-1-piperazinil]metil}-1,3-oksazol-2-il)-1h-indazola kao inhibitori pi3k, namijenjeni upotrebi u liječenju, primjerice, dišnih poremećaja
BR112017010439A2 (pt) composto, composição farmacêutica, combinação farmacêutica, kit, métodos para controle de uma doença fúngica em uma planta e para prevenção ou tratamento de doença fúngica em um indivíduo, e, uso de um composto
UA111725C2 (uk) Кристалічний (r)-(e)-2-(4-(2-(5-(1-(3,5-дихлорпіридин-4-іл)етоксі)-1h-індазол-3-іл)вініл)-1h-піразол-1-іл)етанол
BR112014010401A2 (pt) inibidores do vírus da hepatite c rod-like que contêm o fragmento {2-[4-(bifenil-4-il)-1h-imidazo-2-il] pirrolidina-1-carbonilmetil}amina
EA201691997A1 (ru) Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы
PE20141232A1 (es) Nuevos derivados de ciclohexilamina que tienen actividad como agonistas adrenergicos �2 y como antagonistas muscarinicos m3
PE20140831A1 (es) Nuevo derivado de 1,2,3,4-tetrahidroquinolina util para el tratamiento de diabetes
PE20160550A1 (es) Formulaciones de (s)-3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona
CR20120061A (es) Tableta
BR112015021097A2 (pt) formulações de compostos orgânicos
PE20141337A1 (es) Formulacion de liberacion inmediata de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida
PH12017500718A1 (en) Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with an egfr inhibitor
HRP20171295T1 (hr) Derivat 6-okso-1,6-dihidro-piridazina za upotrebu za liječenje hepatocelularnog karcinoma (hcc)
JP2016533367A5 (es)
BR112015007870A2 (pt) combinação de um derivado de 6-oxo-1,6-di-hidro-piridazina tendo atividade anticâncer com um inibidor de mek
PE20171259A1 (es) Compuestos
MX2016008816A (es) Combinacion de un derivado de 6-oxo-1,6-dihidro-piridazina que tiene actividad anticancer con gefitinib.
AR099035A1 (es) Derivado de 6-oxo-1,6-dihidro-piridazina para usar en el tratamiento de carcinoma de células renales (rcc)
MX2016014948A (es) Sales derivadas de bencisoxazol.

Legal Events

Date Code Title Description
FB Suspension of granting procedure